

**Second Transurethral Resection of Bladder Tumor: Is it Necessary in All T1 and/or High-Grade Tumors?**

Mohsen Ayati<sup>1</sup>, Erfan Amini<sup>1</sup>, Reza Shahrokhi Damavand<sup>1\*</sup>, Mohammad Reza Nowroozi<sup>1</sup>,  
 Mohammad Soleimani<sup>2</sup>, Ehsan Ranjbar<sup>1</sup>, Ali Nowroozi<sup>1</sup>

**Purpose:** To evaluate the role of second transurethral resection of bladder tumor (TURBT) in patients with T1 and/or high-grade bladder tumor regarding tumor size, multiplicity, and presence or absence of muscle in specimens of initial resection.

**Materials and Methods:** A total of 107 patients with either primary T1 or high-grade urothelial bladder cancer underwent second TURBT within 6 weeks after initial surgery and prior to starting intravesical immunotherapy. We assessed the incidence of residual disease and upstaging in second TURBT.

**Results:** Upstaging was noted in 11 (10.3%) patients and residual tumor was evident in 29 (27%) patients. Disease upstaging had a statistically significant association with tumor size, multifocality, and absence of muscle at initial resection in univariate analysis. Presence of residual tumor in second resection also showed significant association with tumor size and absence of muscle at initial resection but not multifocality. Multivariate logistic regression analysis revealed that absence of muscle at initial resection independently predicts disease upstaging during second TURBT (OR = 8.123, 95% CI: 1.478-44.632). Furthermore, both tumor size (OR = 13.573, 95% CI: 3.104-59.359) and absence of muscle (OR = 21.214, 95% CI: 6.062-74.244) were independent predictors of residual disease in second TURBT.

**Conclusion:** We showed that second TURBT in a subset of patients with single, small T1 and/or high-grade tumor who underwent complete initial resection might be of limited value.

**Keywords:** residual tumor; second-look surgery; transurethral resection; upstaging; urinary bladder neoplasms

**INTRODUCTION**

Bladder cancer is the most common malignancy involving the urinary system and the ninth most common cancer throughout the world<sup>(1)</sup>. Based on Globocan data, about 430,000 new cases diagnosed in 2012 with mortality rate of 3.2 and 0.9 per 100,000 men and women respectively<sup>(2)</sup>.

Approximately 70% of urothelial bladder cancers are non-muscle-invasive at presentation. Of these 70% present as stage Ta, 20% as T1 and 10% as carcinoma in situ<sup>(3)</sup>. Transurethral resection of bladder tumor (TURBT) is the initial procedure in the diagnosis and treatment of these tumors.

Different studies have reported presence of residual disease in about 40% of high-grade Ta and up to 55% of patients with T1 tumors, after initial resection<sup>(4-7)</sup>. Moreover, there is significant potential for risk of understaging in patients with high-grade non-muscle-invasive tumors in the initial resection especially those with T1 tumors<sup>(8,9)</sup>. So, many investigators recommended that patients with Ta high-grade and or T1 tumors should undergo second TURBT.

However, despite the fact that many retrospective studies showed a high rate of residual tumor and under-

staging after repeat TURBT, several factors including surgeon experience and quality of initial resection in addition to tumor characteristics might affect the results of these reports<sup>(10-12)</sup>. Some of these studies included patients with even macroscopic residual tumor. Presence of macroscopic residual tumor may lead to erroneous conclusions in such studies and overestimate the significance of second TURBT. Furthermore, only few investigators have evaluated the role of second TURBT in a subgroup of patients with single and small T1 and/or high-grade tumors and those who underwent initial complete TURBT.<sup>(6,11,13)</sup>

Because of ongoing debate concerning the indications of second TURBT and to identify groups of patients who may benefit most from a second TURBT, we evaluated the role of second TURBT in a series of 107 patients with high-grade non-muscle-invasive bladder tumor who had a second TURBT regarding tumor size, multiplicity and presence or absence of muscle in specimens of initial resection.

**PATIENTS AND METHODS****Study population**

Using our institutional review board-approved bladder

<sup>1</sup> Department of Urology, Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

<sup>2</sup> Department of Urology, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

\*Correspondence: Department of Urology, Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Tel: +98 21 66903063. Fax: +98 21 66903063. E-mail: rshahrokhi@razi.tums.ac.ir.

Received July 2018 & Accepted August 2018

**Table 1.** Pathologic findings at second TURBT stratified according to tumor characteristics during initial resection.

First TURBT Tumor characteristics		Distribution no. (%)	Tumor stage at second TURBT			
			T0, no. (%)	Ta, no. (%)	T1, no. (%)	T2, no. (%)
Size	≤ 3 cm	87(81.3)	73(84)	10(11.5)	3(3.4)	1(1.1)
	>3 cm	20(18.6)	5(25)	8(40)	1(5)	6(30)
Multifocality	Single	92(86)	69(75)	16(17.3)	3(3.2)	4(4.3)
	Multiple	15(14)	9(60)	2(13.3)	1(6.6)	3(20)
Muscle in the specimen	Present	73(68.2)	67(91.8)	4(5.4)	1(1.4)	1(1.4)
	Absent	34(31.7)	11(32.3)	14(41.1)	3(8.8)	6(17.6)
Overall		107(100)	78(72.9)	18(16.8)	4(3.7)	7(6.5)

cancer database, we retrospectively evaluated all patients who underwent second TURBT between 2011 and 2015. Definition of second TURBT was based on undergoing second resection within 6 weeks from initial surgery. Tumor size was determined based on the ultrasonography findings. In this retrospective analysis of prospectively collected data, patients with macroscopic residual disease after initial TURBT according to the surgeon's subjective observation were excluded from enrollment. In addition, patients with muscle invasive disease after initial resection who underwent second TURBT (i.e. as a part of bladder preservation protocol) were excluded from enrollment. Receiving intravesical immunotherapy after initial TURBT and prior to second resection was also an additional exclusion criterion. Administration of intravesical mitomycin after TURBT was done based on the decision of treating urologist. A total of 107 patients met inclusion criteria and were enrolled in the analysis.

### Surgical technique

Initial TURBTs were performed by a limited number of expert urologists and visible tumors with adequate margin were resected separately in fractions. During the second TURBT, all visible tumors and scars from previous surgery were resected. All TURBTs were performed using monopolar loop electrocautery employing distilled water as solution. Staging was performed according to the TNM 2009 system of the American Joint Committee on Cancer (AJCC) and tumors were graded based on 2004 WHO grading classification.

### Outcome assessment

The incidence of residual disease, tumor upstaging, and upstaging to muscle-invasive disease were the outcome measures of the study. The collected data were analyzed using SPSS software (version 16, SPSS Inc, Chicago, IL, USA). Categorical data were compared using chi-square or fisher's exact test and quantitative variables were compared using *T*-Test. Multivariate logistic regression analysis was used to determine variables that

independently predict risk of upstaging/residual disease.

## RESULTS

Among 107 patients, 90 (84%) were male and 17 (16%) female. The mean age was 59±12 years (range from 24 to 80). Ninety-two patients had a single tumor and the remaining (14%) had multifocal tumors. Histopathological evaluation after initial TURBT revealed 4 high-grade Ta and 103 T1 tumors.

Residual tumor was detected in 29 (27%) patients after second resection and upstaging occurred in 11 (10.3%) cases. Upstaging to muscle-invasive disease occurred in 7 patients of whom 6 patients did not have muscle in the initial specimen. **Table 1** shows pathologic findings in second TURBT stratified according to various tumor characteristics in initial surgery. The association of tumor size, multifocality, and absence of muscle in initial resection with the risk of residual disease and upstaging has been shown in **Table 2**. Disease upstaging had a statistically significant association with tumor size, multifocality, and absence of muscle at initial resection in univariate analysis. Presence of residual tumor in second resection also showed significant association with tumor size and absence of muscle at initial resection but not multifocality. Multivariate logistic regression analysis (**Table 3**) revealed that absence of muscle at initial resection can independently predict disease upstaging during second TURBT. Furthermore, both tumor size and absence of muscle were independent predictors of residual disease in second TURBT.

Among 59 patients with single, small (≤ 3cm) tumors who underwent adequate initial resection, identified by the presence of muscularis propria in the specimen, upstaging was not found and only 3 patients showed residual disease in second TURBT.

## DISCUSSION

Approximately 70% of patients who present with blad-

**Table 2.** Association between baseline tumor characteristics and disease upstaging/residual disease.

Tumor characteristics in first TURBT		Residual tumor (%)	<i>P</i> -value	Upstaging to muscle- invasive disease (%)	<i>P</i> -value	Upstaging (%)	<i>P</i> -value
Tumor size	≤3 cm	14 (16.1)	< 0.001	1 (1.1)	< 0.001	4 (4.6)	< 0.001
	>3 cm	15 (75.0)		6 (30)		7 (35.0)	
Tumor multifocality	Single	23 (25.0)	0.226	4 (4.3)	0.023	7 (7.6)	0.024
	Multifocal	6 (40.0)		3 (20)		4 (26.7)	
Presence of muscle in the specimen	Present	6 (8.2)	< 0.001	1 (1.4)	0.002	2 (2.7)	< 0.001
	Absent	23 (67.6)		6 (17.6)		9 (26.5)	

**Table 3.** Multivariate Regression analysis to predict risk of residual tumor and disease upstaging.

Tumor characteristics in first TURBT	Risk of residual tumor, OR [95% CI]	P-value	Risk of upstaging to muscle-invasive disease, OR [95% CI]	P-value	Risk of upstaging, OR [95% CI]	P-value
Tumor size (>3 cm vs. ≤3 cm)	13.573 [3.104-59.359]	0.001	17.069 [1.632-178.482]	0.018	4.707 [0.990-22.379]	0.052
Tumor multifocality (Multifocal vs. Single)	-	-	2.048 [0.285-14.736]	0.476	2.508 [0.443-14.203]	0.299
muscle in the specimen (Absent vs. present)	21.214 [6.062-74.244]	<0.001	6.517 [0.641-66.206]	0.113	8.123 [1.478-44.632]	0.016

der cancer have non-muscle-invasive disease and TURBT remains the treatment of choice in these patients. Adequate resection of bladder tumor during TURBT is of utmost importance. All macroscopic tumors with underlying muscle as well as edge of the resection area, preferably in fractions, should be removed. This allows the histopathologist to accurately stage the disease and decreases risk of understaging and inadequate treatment. Klan et al demonstrated that patients who initially had a fractionated TURBT had a reduced rate of residual tumor (36.7%) compared to patients who did not undergo resection of the tumor bed (56%)<sup>(14)</sup>.

The results of the second TURBT mainly reflect the quality of initial resection. However, because of factors such as anatomic inaccessibility, tumor multiplicity, excessive tumor volume or medical instability requiring premature cessation, complete tumor removal is not always possible. Recent studies have suggested that initial TURBT may be incomplete in a significant number of cases<sup>(4,12,14,15)</sup>. Therefore, presence of residual tumor or upstaging during second TURBT could be a consequence of incomplete initial resection. Furthermore, several prognostic factors i.e. multifocality, tumor size and absence of muscle in the first resection might also impact the outcome of second TURBT. Most data on second TURBT come from studies, which did not specifically analyze aforementioned prognostic factors in the first resection which are also important.

Risk of residual disease and upstaging in second TURBT vary from 26 to 83% and 1.3 to 64% in different studies, respectively<sup>(13,16-20)</sup>. Although the term second TURBT should not be used for the repeat resection after incomplete TURBT with macroscopic residual disease, several studies addressing significance of second TURBT are retrospective with the potential of including patients with incomplete initial resection. In a series of 58 patients with G2-3 pT1 bladder cancer a rate of 74% of residual tumors in second TURBT has been reported. However, information regarding the quality of first resection was not available. In addition, muscle was not present at initial resection in about 40% of patients, questioning the quality of resection<sup>(18)</sup>. To evaluate the value of second TURBT for T1 bladder cancer, Schwaijbold et al reported 52% residual disease in 136 patients who underwent second TURBT because of T1 urothelial cancer in initial resection. However, the study population consisted of relatively high-risk patients as more than 25% of patients had recurrent disease<sup>(21)</sup>.

As mentioned before, Multifocality and tumor size may influence the risk of residual tumor and/or upstaging in second TURBT. In a randomized prospective study investigators performed complete and correct resection during the first TURBT and showed a rate of 33.3% of residual tumor in 105 patients who underwent re-TURBT, 2-6 weeks following primary diagnosis of T1 disease<sup>(11)</sup>. Patients with no muscle tissue in the specimen

were excluded from the study. In patients with solitary tumor, they reported 22.6% and 5.7% residual mass and upstaging respectively. Also in tumors less than 3cm, the rate of residual disease and upstaging in second TURBT was 18.9% and 2.7% respectively. These results are similar to our findings and corroborate with our observations (Table 2). Similarly, in a prospective study, the authors reported a rate of 36.8% of residual tumor in 38 patients with single tumor versus 64.3% in patients with multifocal disease<sup>(22)</sup>. In the present study, we also noted that 25% of patients with single tumor had residual cancer in second TURBT, whereas risk of residual disease was 40% in patients with multiple tumors; however the difference was not statistically significant.

Several investigators showed that absence of detrusor muscle in initial specimen significantly increases the risk of residual disease and upstaging in second resection<sup>(17,18)</sup>. Our findings in this study support this notion. Of 73 patients with muscle in the initial resection, 6 (8.2%) had residual tumor. Of these, only 2 patients had upstaging. On the other hand, 23 of 34 patients (67.6%) without muscle at first resection had residual tumor, and upstaging occurred in 26.5% of them.

A major problem associated with TURBT is understaging. In a retrospective study 27% of T1 tumors were upstaged after radical cystectomy (RC)<sup>(23)</sup>. Similarly, Stein reported that one-third of patients believed to have non-muscle-invasive cancer at the time of cystectomy were found to have muscle-invasive disease<sup>(24)</sup>. The risk increased to 50% in some RC series<sup>(25)</sup>. However, these findings are not attributable to all high-grade or T1 tumors in second TURBT as the majority of patients with non-muscle-invasive disease in RC cohorts may harbor poor prognostic clinical and radiological features including multiple large tumors or refractory to intravesical therapy<sup>(17)</sup>.

Performing TURBT according to a "well-standardized strategy" decreases the likelihood of residual tumor and upstaging in patients with superficial disease. This issue has been confirmed in recent studies with report of 26-43% and 1.3-8.2% residual tumor and upstaging respectively<sup>(13,15,19,20,26,27)</sup>. In our study, residual tumor was also detected in 27% of patients and upstaging occurred in 10.3%. Nevertheless, present study questioned the importance of second TURBT in a subset of patients with single and small tumors (≤ 3cm), especially when muscle is present in first specimen. It should be considered that omitting second TURBT in this subgroup of patients is not equal to overlooking follow up evaluations. Actually these patients will undergo cystoscopy within 3 months after TURBT and all potential residual tumors can be detected at that time.

Limitation of this study is mainly related to the retrospective nature of the study. It comprised patients with relatively low-risk disease as 81.3% and 86% of

patients had small ( $\leq 3$  cm) and single tumors respectively. Low incidence of disease upstaging could also be a result of clinical characteristics of the study cohort. In addition, in this multi-institutional study specimens were assessed in different pathology departments and slides were not re-reviewed for the purpose of the study. Another limitation of this cohort is the very low sample size of high-grade Ta. However, it should be considered that our finding for T1 tumors (majority of them were also high grade) can be generalized to Ta tumors. Ta tumors are probably associated with even lower risk of residual disease and upstaging in second TURBT. Finally, we couldn't assess the site of initial tumors in bladder, because it is not recorded in our data registry. Nevertheless, our study showed that Subjecting all patients with T1 and/or high-grade urothelial cancer to repeat TURBT has the potential to impose unnecessary risk and additional financial burden. Further studies are needed to identify subgroups of patients that may benefit most from second TURBT.

### CONCLUSIONS

We showed that absence of muscle in first resection can independently predict risk of upstaging and residual disease in second TURBT. According to our findings, second TURBT might be overtreatment in a significant proportion of patients with high-grade and/or T1 disease and in contrast to prior reports it does not seem to be necessary in all patients with T1 and/or high-grade tumors. We noted that second TURBT in patients with single, small T1 and/or high-grade tumors who underwent adequate initial resection is not associated with upstaging or residual disease.

### CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

### REFERENCES

1. Ploeg M, Aben KK, Kiemeny LA. The present and future burden of urinary bladder cancer in the world. *World J Urol.* 2009;27:289-93.
2. Organization WH. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon, France: International Agency for Research on Cancer. 2014.
3. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. *Urology.* 2005;66:4-34.
4. Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. *J Urol.* 2003;170:433-7.
5. Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. *J Urol.* 2006;175:1641-4.
6. Lazica DA, Roth S, Brandt AS, Bottcher S, Mathers MJ, Ubrig B. Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. *Urol Int.* 2014;92:131-5.
7. Vasdev N, Dominguez-Escrig J, Paez E, Johnson MI, Durkan GC, Thorpe AC. The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer. *Ecancermedicalscience.* 2012;6:18.
8. Gendy R, Delprado W, Brenner P, et al. Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series. *BJU Int.* 2016;4:54-9.
9. El-Barky E, Sebaey A, Eltabey M, Aboutaleb A, Hussein S, Kehinde EO. The importance of second-look transurethral resection for superficial bladder cancer. *Journal of Clinical Urology.* 2015;8:299-305.
10. Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. *Eur Urol.* 2002;41:523-31.
11. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. *Eur Urol.* 2010;58:185-90.
12. Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer. *Urology.* 2002;60:822-4.
13. Divrik T, Yildirim U, Eroglu AS, Zorlu F, Ozen H. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? *J Urol.* 2006;175:1258-61.
14. Klan R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. *J Urol.* 1991;146:316-8.
15. Schips L, Augustin H, Zigeuner RE, et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? *Urology.* 2002;59:220-3.
16. Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B. The value of a second transurethral resection in evaluating patients with bladder tumours. *Eur Urol.* 2003;43:241-5.
17. Dutta SC, Smith JA, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. *The Journal of urology.* 2001;166:490-3.
18. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. *J Urol.* 1999;162:74-6.

19. Zurkirchen MA, Sulser T, Gaspert A, Hauri D. Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists. *Urol Int.* 2004;72:99-102.
20. Hashine K, Ide T, Nakashima T, Hosokawa T, Ninomiya I, Teramoto N. Results of second transurethral resection for high-grade T1 bladder cancer. *Urol Ann.* 2016;8:10-5.
21. Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. *BJU Int.* 2006;97:1199-201.
22. Gill TS, Das RK, Basu S, Dey RK, Mitra S. Predictive factors for residual tumor and tumor upstaging on relook transurethral resection of bladder tumor in non-muscle invasive bladder cancer. *Urol Ann.* 2014;6:305-8.
23. Chang BS, Kim HL, Yang XJ, Steinberg GD. Correlation between biopsy and radical cystectomy in assessing grade and depth of invasion in bladder urothelial carcinoma. *Urology.* 2001;57:1063-6.
24. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. *J Clin Oncol.* 2001;19:666-75.
25. Fritsche HM, Burger M, Svatek RS, et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. *Eur Urol.* 2010;57:300-9.
26. Vogeli TA, Grimm MO, Simon X, Ackermann R. [Prospective study of effectiveness. Reoperation (re-TUR) in superficial bladder carcinoma]. *Urologe A.* 2002;41:470-4.
27. Jakse G, Algaba F, Malmstrom PU, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why? *Eur Urol.* 2004;45:539-46.